Patients can call 833-EYE-GENE for more information. For people who qualify, Genentech offers patient assistance programs ...

Genentech raised nearly $2 billion during its second initial public offering (IPO) on July 20 when Roche Holding refloated part of the company after acquiring all outstanding shares in June ...

For people who qualify, Genentech offers patient assistance programs through Genentech Access Solutions. More information is also available at (866) 4ACCESS/(866) 422-2377 or https://www.Genentech ...

Patients can call 833-EYE-GENE for more information. For people who qualify, Genentech offers patient assistance programs through Genentech Access Solutions. More information is also available at (866 ...

A four-year battle over one of the most ubiquitous patents in biotech ended with the US Patent and Trademark Office (USPTO) coming down on Genentech's side. The decision, reached in February ...

Genentech applies that same science-driven, patient-centric approach to identifying policy solutions that drive access while preserving the innovation that allows the U.S. healthcare system to thrive.

October 18, 2024--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from the open-label, single-arm Phase IV ...

– The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME treated with Vabysmo who identify as African American, Black, Hispanic and ...